Decreased plasma concentration of a novel anti-inflammatory protein--adiponectin--in hypertensive men with coronary artery disease.
OBJECTIVE
Recent studies indicate that adiponectin may have anti-inflammatory and anti-atherogenic properties, suggesting that hypoadiponectinemia can play a role in the pathogenesis of cardiovascular disease. Therefore the aim of the study was to assess plasma adiponectin concentration in hypertensive male patients with coronary artery disease (CAD). Associations of adiponectinemia with other cardiovascular risk factors were also analysed.


RESULTS
The study included 99 consecutive male patients (median age 57 years) with hypertension and CAD who at the same time underwent coronary and renal angiography. The control group consisted of 62 BMI-matched healthy male blood donors (median age 48 years). Plasma adiponectin level was significantly lower in the CAD group as compared to the control group (4.01 +/- 0.18 vs. 4.88 +/- 0.24 microg/ml; p<0.01). There were no differences in plasma adiponectin concentration between hypertensive CAD patients with and without atherosclerotic renal artery stenosis. In the CAD group plasma adiponectin concentration correlated with levels of creatinine (r=0.56; p<0.001), HDL cholesterol (r=0.24; p<0.05), BMI (r=-0.33; p<0.001), glucose (r=-0.22; p<0.05) and triglycerides (r=-0.25; p<0.05). No correlation was found between plasma adiponectin and homocysteine concentrations. In a multivariate stepwise logistic regression model increasing concentrations of adiponectin were independently and significantly associated with a lower risk of CAD (OR 0.58 95% CI 0.42-0.81 p<0.001).


CONCLUSIONS
Our results showed decreased plasma adiponectin concentration in the studied group of hypertensive men with CAD as compared to normotensive healthy subjects. This may suggest that decreased plasma adiponectin concentration is associated with a higher risk of CAD.
Department of Coronary Heart Disease, Institute of Cardiology, Alpejska 42, 04-628 Warsaw, Poland.
Zofia
Z
Dzielińska
Andrzej
A
Januszewicz
Andrzej
A
Wiecek
Marcin
M
Demkow
Magdalena
M
Makowiecka-Cieśla
Aleksander
A
Prejbisz
Jacek
J
Kadziela
Ryszard
R
Mielniczuk
Elzbieta
E
Florczak
Jadwiga
J
Janas
Magdalena
M
Januszewicz
Witold
W
Ruzyłło
D052242:Adiponectin; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000097:blood; D015897:Comorbidity; D003324:Coronary Artery Disease / Q000097:blood* / Q000453:epidemiology*; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000453:epidemiology*; D036341:Intercellular Signaling Peptides and Proteins; D008297:Male; D008875:Middle Aged; D011044:Poland / Q000453:epidemiology; D011506:Proteins / Q000032:analysis*; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors
D052242:Adiponectin; D000893:Anti-Inflammatory Agents; D036341:Intercellular Signaling Peptides and Proteins; D011506:Proteins